Summit Therapeutics’ CRL Shock: Share Slump, FDA Rejection, and Future Outlook
Summit Therapeutics’ stock plunged after the FDA issued a CRL for its NSCLC drug ivonescimab, exposing efficacy gaps and shaking investor confidence in its oncology push.
3 minutes to read


